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Nicotinea b s t r a c t
Joint physiologically-based toxicokinetic and toxicodynamic (PBTK/TD) modelling was applied to simu-
late concentration–time proﬁles of nicotine, a well-known stimulant, in the human body following single
and repeated dosing. Both kinetic and dynamic models were ﬁrst calibrated by using in vivo literature
data for the Caucasian population. The models were then used to estimate the blood and liver concentra-
tions of nicotine in terms of the Area Under Curve (AUC) and the peak concentration (Cmax) for selected
exposure scenarios based on inhalation (cigarette smoking), oral intake (nicotine lozenges) and dermal
absorption (nicotine patches). The model simulations indicated that whereas frequent cigarette smoking
gives rise to high AUC and Cmax in blood, the use of nicotine-rich dermal patches leads to high AUC and
Cmax in the liver. Venous blood concentrations were used to estimate one of the most common acute
effects, mean heart rate, both at rest and during exercise. These estimations showed that cigarette
smoking causes a high peak heart rate, whereas dermal absorption causes a high mean heart rate over
48 h. This study illustrates the potential of using PBTK/TD modelling in the safety assessment of
nicotine-containing products.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction increase heart rate, affect the nervous system and inﬂuence otherNicotine, a commonly used stimulant, has been investigated
extensively in previous years, both in terms of in vivo and in vitro
effects on human body. This psychoactive substance is known tobiological processes including behavioural effects and metabolic
responses (Fattinger et al., 1997; Perkins, 1992). Nicotine is an
addictive drug and its consistent use is likely to result in the devel-
opment of tolerance to (and dependence on) its actions. Cigarette
smoking, as a delivery mechanism, is inherently more likely to pro-
duce addiction due to the extremely rapid pulmonary absorption
of nicotine, occurring at a rate similar to intravenous administra-
tion (de Landoni, 1991). There is therefore interest in the develop-
ment of nicotine replacement therapies based on alternative
exposure routes (e.g., coated tablets, chewing gum, nasal spray,
inhalator, microtablets and transdermal patches). Cigarettes vary
in their nicotine content: the tobacco from bidi cigarettes has on
average 21.2 mg/g of nicotine compared to the tobacco from ﬁl-
tered and unﬁltered commercial cigarettes containing 16.3 and
13.5 mg/g of nicotine, respectively (Malson et al., 2001). To esti-
mate a daily nicotine consumption, Benowitz et al. (1982) reported
that low-, and high- nicotine commercial cigarettes deliver (with
Federal Trade Commission [FTC] smoking machine) 1.2, 0.4 and
2.5 mg of nicotine, respectively. Transdermal patches, on the other
hand, normally deliver from 5 to 30 mg nicotine and are applied
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than 100% of the nicotine absolute dose in a patch reaches systemic
circulation. The amount of nicotine absorbed has been reported to
be between 65% and 90% of the total dose (Bannon et al., 1989;
Gupta et al., 1993). This absorption was found independent of a
dose and the undelivered amount is believed to be lost either by
evaporation or possible skin metabolism.
Papathanasiou et al. (2013) recently studied the effect of nico-
tine smoking on heart rate at rest and during exercise in 298 young
adults. The authors concluded that smokers had signiﬁcantly
higher resting heart rate values than non-smokers but the reverse
was observed during exercise. The maximal values achieved during
exercise were around 191–193 [bpm] (smokers) and 198–199
[bpm] (non-smokers).
There are many literature studies and reviews describing in
detail the absorption, distribution, metabolism and excretion
(ADME) processes of nicotine (Benowitz, 1990; Hukkanen et al.,
2005).
Nicotine is a water and lipid soluble drug which, in the free base
form, is readily absorbed via respiratory tissues, skin, and the gas-
trointestinal (GI) tract. Plasma protein binding was reported to be
only around 5% (Yamazaki and Kanaoka, 2004). Nicotine readily
reaches organs and tissues and undergoes extensive metabolism
mainly in the liver by cytochrome P450 enzymes (mostly CYP2A6,
and also by CYP2B6). A major metabolite of nicotine is cotinine (ca.
80% of nicotine conversion). Other metabolites include nicotine N0-
oxide, nornicotine, nicotine isomethonium ion, 2-hydroxynicotine
and nicotine glucuronide. Renal clearance accounts for up to 35%
of total nicotine clearance (Tutka et al., 2005). Additionally, there
are observed differences in plasma concentrations between smok-
ers and nonsmokers suggesting differences in total clearance rates,
with non-smokers showing faster clearance than smokers (Tutka
et al., 2005; Yun et al., 2008). The apparent volume of distribution
of nicotine was determined in one clinical study to be 2.0 L/kg in
smokers and 3.0 L/kg in nonsmokers (Ellenhorn, 1988).
Due to rich literature resources and experimental data availabil-
ity nicotine is a good candidate for further elaboration of joint Phys-
iologically-based Toxicokinetic/Pharmacokinetic (PBTK/PBPK) and
Toxicodynamic/Pharmacodynamic (PBTD/PBPD) models. More-
over, nicotine has a rapid onset of action therefore it can be used
to model observable acute effects. Toxicodynamics is however a
highly complex process and sensitive to the development of a phys-
iological tolerance with respect to stimulant dose–response rela-
tionships. The theoretical framework should consequently be able
to account for such ‘‘force-driving’’ tolerance and thereby reduce
the effect of the drug (for instance, via incorporation of a ‘‘toler-
ance’’ compartment representing a hypothetical noncompetitive
antagonist receptor, as described below). Various PBTK–TD models
for nicotine are reported in the literature (Green et al., 1999;
Porchet et al., 1988; Robinson et al., 1992; Teeguarden et al.,
2013) and all present relatively simple but nevertheless satisfactory
representations of the nicotine ADME process following the inhala-
tion, dermal, and oral exposure routes.
The aim of this study was to apply a reﬁned PBTK model (with
the addition of sub-compartments in skin and GI tract and
modiﬁcation for drug effects) with respect to models previously
developed in the scientiﬁc literature to simulate selected daily
exposure scenarios of nicotine (both in terms of cigarette smoking
and nicotine replacement therapy). The internal blood and liver
concentrations are deﬁned by the Area Under Curve (AUC) and
the peak concentration (Cmax) and are linked to the TD model
which estimates one of the common acute effects, heart rate (mean
and its trend in time), both at rest and during cycling exercise. This
study builds on previous work by further applying PBTK/TD mod-
elling to analyse nicotine ADME proﬁles resulting from various
exposure conditions based on both single and repeated dosing.2. Materials and methods
2.1. Experimental data used to calibrate and validate the PBTK model
For the purpose of this study we used the most complete in vivo
dataset we could ﬁnd in the public literature for the Caucasian
population. For calibration of liver metabolism rates of nicotine to
cotinine intravenous experimental data were used (Porchet et al.,
1988). In this study, eight healthy subjects (all habitual smokers),
in a state of rest, were given two intravenous (i.v.) administrations
of nicotine (2.5 lg of nicotine per kg body weight (BW) per min for
30 min) at intervals of 1, 2 and 3.5 h. For validation, blood data of
nine subjects after i.v. injection of nicotine (ca. 0.7 lg/kg BW per
min for 180 min) were chosen (Fattinger et al., 1997).
For calibration of the oral PBTK model, single and repeated
doses (once every 1.5 h for 12 h) of nicotine (4, 8, 12 mg) were
ingested orally via a drinking straw (containing loose nicotine
bitartrate particles) in a group of 24 smokers (D’Orlando and Fox,
2004). Mean plasma concentrations were calculated from individ-
ual nicotine levels presented in the paper. For validation purposes,
nicotine-containing capsules coated with a polyacrylic carbomer,
Carbopol 974P, (6 and 15 mg) were administered as a single dose
to 12 subjects, all non-smokers (Green et al., 1999). Mean experi-
mental serum nicotine concentrations were used from this study.
For calibration of the dermal PBTK model, nicotine patches
(Nicolan™) were applied in various doses (15, 30 and 60 mg)
directly to the skin of healthy human volunteers (all smokers) for
24 h as single doses and 30 mg applied in repetitive way once
every 24 h for 7 days (Bannon et al., 1989). Mean measured plasma
nicotine concentrations were published. For validation purposes,
single and multiple applications of a nicotine transdermal system
(NTS) were investigated on 13 healthy adult male smokers
(1.5 mg/h of nicotine released over 24 h) (Gupta et al., 1993). Mean
experimental plasma nicotine concentrations were presented.
For calibration of the inhalation PBTK model, cigarettes deliver-
ing nicotine doses of 0.4, 1.2, 2.5 mg were smoked (30 per day, with
FTC smoking machine) by 12 healthy volunteers (all smokers)
(Benowitz et al., 1982). Mean blood nicotine concentrations were
measured. For validation, we used the inhalation of 0–64 mg/mL of
nicotine by 24 healthy non-smoking subjects (Hansson et al., 1994).
2.2. Experimental data used to develop the PBTD model
The toxicodynamic model of heart rate was developed using
data published by Porchet et al. (1988) and validated using exper-
imental results of Fattinger et al. (1997). In both cases, heart rate
responses to intravenous nicotine were measured at rest.
To simulate the effect of nicotine on heart rate during exercise,
a literature study was chosen in which the effects of nicotine
(transdermal 7 mg-nicotine patch) were measured on cycling
endurance. The study was carried out on twelve healthy males
who were non-smokers (Mündel and Jones, 2006).
2.3. Structure and parameters of the PBTK–TD models
2.3.1. PBTK model
The schematic representation of the PBTK model is shown in
Fig. 1. The model consists of three compartments describing: (i)
the inhalation process (inhaled and exhaled air linked to the lungs)
(Kumagai and Matsunaga, 1995); (ii) the GI tract with 6 sub-
compartments (for oral exposure only), Fig. 2; and (iii) the skin
with the surface compartment and 4 skin sub-compartments (for
dermal exposure only), Fig. 3. The sub-compartments serve to
account for the complexity of the absorption process (especially
the associated time-lag). Transport through all the organs, except
for the skin layers is described by ordinary differential equations.
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Fig. 1. General structure of the PBTK model.
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ered: administration via a straw and via dissolution from a coated
tablet. A ﬁrst-order rate of absorption from stomach, small and
large intestine and stomach emptying rates are included according
to Loizou and Spendiff (2004). Absorbed quantities are directed to
the liver.A
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Fig. 3. Skin divided into sub-comThe skin is divided into stratum corneum, viable epidermis and
dermis with blood mix. Uni-dimensional diffusion describes the
transport in the skin according to Fick’s second law with speciﬁed
initial and boundary conditions (partial differential equations). The
diffusion coefﬁcient is different for stratum corneum and viable epi-
dermis but assumed constant through the process of absorption.
The other organs/bio-ﬂuids such as liver, kidney, adipose tissue,
highly-perfused tissues, heart, brain, poorly-perfused tissues, and
blood are single perfusion and accumulation sites in the model.
Metabolism is assumed to occur only in the liver and excretion
via urine and bile (to a lesser extent) is described by a ﬁrst-
order-rate constant. All the organs and blood are homogeneous
with respect to the concentration of a chemical. Transport between
blood and tissues is assumed to be ﬂow-limited (transport barriers
between free molecules of chemical in blood and tissue are negli-
gible) and equilibrium between free and bound fractions in blood
and tissue is instantaneous. It is further assumed that plasma
accounts for 55% of blood volume and that the difference between
blood and plasma levels is deﬁned by a ratio coefﬁcient. The model
simulations for single and repeated dosing are carried out for the
same ADME parameters.
The model equations are given in Appendix 1.
All physiological parameters for a reference man and woman
are given in Table 1, after Brown and colleagues (Brown et al.,
1997) and after (Kumagai and Matsunaga, 1995) for the respiratory
parameters.
Optimization was performed for the most sensitive parameters
(with respect to AUC in blood/plasma) identiﬁed by the Sensitivity
Analysis according to Soetaert and Petzoldt (Soetaert and Petzoldt,
2010; Soetaert, 2010). These parameters were: nicotine metabo-
lism rate to cotinine (Vmax), nicotine dissolution from a tablet in
the stomach (Diss), absorption from stomach (kastm) and small
intestine (kaSI), diffusion coefﬁcient in stratum corneum (DSC),BS. LARGE INTST
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Table 1
Physiological parameters for a reference woman and man.
Quantity Reference woman Reference man
Average body weight [kg] 60 75
Organ weights fractions (fractions of body weight)
Liver 0.026 0.026
Adipose tissue 0.254 0.140
Lungs 0.0105 0.012
Kidney 0.0044 0.0044
Heart 0.0044 0.0044
Brain 0.02 0.02
GI tract 0.0265 0.025
Stomach 0.00337 0.00318
Small intestine 0.0146 0.0138
Large intestine 0.0085 0.0080
Poorly perfused tissues 0.36 0.42
Skin 0.08 0.108
Remaining organs/tissues 0.149 0.169
Blood 0.065 0.072
Venous blood 0.04875 0.054
Thickness of: skin, viable epidermis, stratum corneum [cm] 0.204, 0.0032, 0.0018 0.2906, 0.0047, 0.0017
Regional blood ﬂow rates [fraction of cardiac output [L/h]
Cardiac output [L/h] 15BW0.74 15BW0.74
Liver 0.25 0.24
Adipose tissue 0.055 0.04
Lungs 0.025 0.025
Kidney 0.19 0.2
Heart 0.04 0.04
Brain 0.114 0.144
Poorly perfused tissues 0.135 0.16
GI tract 0.14 0.13
Fractions of GI tract ﬂow to stomach, small and large intestine 0.2, 0.6, 0.2 0.2, 0.6, 0.2
Skin 0.05 0.05
Remaining organs/tissues 0.001 0.001
Alveolar ventilation ALV [L/h] 288.549 326.8275
Respiratory rate RR [1/h] 840 (at rest) 840 (at rest)
1080 (at exercise) 1080 (at exercise)
Mucous layer or inhaled/exhaled air VAT [L] 0.1 (optimized) 0.2 (optimized)
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and stratum corneum (PCSC), nicotine water/air partition coefﬁcient
(PCwater,air).
Optimization was carried out by applying the Levenberg–Mar-
quardt algorithm to nonlinear data ﬁtting (Moré, 1978). The
parameters were optimized always with respect to in vivo blood/
plasma nicotine concentrations of smokers.
Diffusion and partition coefﬁcients in viable epidermis were
calculated by literature quantitative–structure activity relation-
ships (QSARs) for skin permeation (median values were chosen):
diffusion coefﬁcient (Cleek and Bunge, 1993; Krüse et al., 2007;
McCarley and Bunge, 2001; Yamaguchi et al., 2008) and stratum
corneum/viable epidermis partition coefﬁcient (Chinery and
Gleason, 1993; McCarley and Bunge, 2001; Polak et al., 2012;
Yamaguchi et al., 2008). The blood/air partition coefﬁcient was also
estimated using QSAR equations (Buist et al., 2012).
Tissue-to-blood partition coefﬁcients for nicotine and cotinine
were determined according to Schmitt (2008). The model calcu-
lates steady-state tissue: plasma partition coefﬁcients based on
the composition of the tissues in terms of water, neutral lipids,
neutral and acidic phospholipids and proteins using the lipophilic-
ity, the binding to phospholipid membranes, the pKa and the
unbound fraction in blood plasma as compound speciﬁc parame-
ters. For nicotine, calculations were done for pKa = 8, LogPoct = 1.17
(octanol–water partition coefﬁcient) and fu = 0.95 (fraction
unbound to proteins).
Metabolism of nicotine to cotinine in the liver is assumed to
follow Michaelis–Menten kinetics. Metabolism to other substances
in the liver follows ﬁrst- order reaction rate with a rate
constant- Kmet [L/h].
Table 2 provides the list of all the values of the PBTK model
parameters.2.3.2. PBTD model
The PBTD model is in accordance with the previously published
nicotine-effect model (sigmoid Emax model) in which a ‘‘tolerance’’
compartment represents a hypothetical noncompetitive antagonist
(Porchet et al., 1988) – Fig. 4. Use of this model in predicting tox-
icodynamics has already been explained in Holford and Sheiner
(1981)). The modiﬁcation in the model, introduced for a better ﬁt
and better description of pharmacological response curves,
includes the addition of an exponent in the considered concentra-
tions to modify the hyperbolic form of the original model (Eqs. (1)
and (3)) (Davey et al., 1976).
In this work, we assume, in accordance with the model ﬁtting
results to available literature data, that this modiﬁcation is neces-
sary for the case of nicotine effects during exercise only. As in the
paper of Porchet et al. (1988) to avoid identiﬁability problems, we
additionally assume that the chemical concentration in blood
(Cven) is always much less than the concentration needed to pro-
duce half of the maximal effect (Cven,50), i.e., Cven <<< Cven,50. Antag-
onist (tolerance) formation and elimination rates are assumed to
constant (Eq. (2)) and are dependent on venous blood concentra-
tion of a stimulant. Since, however, it is only the unbound fraction
of a drug in blood that causes an effect, the venous blood concen-
trations are corrected by the protein-binding coefﬁcient (fu).
Modiﬁed sigmoid model with hypothetical noncompetitive
antagonist (Porchet et al., 1988):
E ¼ E0 þ
Emax
Cyven;50
 Cyven
1þ C
y
Ant
Cy
Ant;50
 
 1þ Cyven
Cy
ven;50
   E0 þ
Emax
Cyven;50
 Cyven
1þ C
y
Ant
Cy
Ant;50
! E
¼ E0 þ S  C
y
ven
1þ C
y
Ant
Cy
Ant;50
ð1Þ
Table 2
ADME parameters for nicotine.
Parameter Value References
Liver metabolism
To cotinine: Vmax [mg/h/BW] 28.1 nmol/mg of protein/h - > 319.785 mg/h- >
11.260 [mg/h/BW]; microsomal protein yield:
34–42 mg/g liver; (we took mean value)
38 mg/g liver
Optimized for (Fattinger et al., 1997; Porchet
et al., 1988); Originally from Messina et al.
(1997); scaled up according to Pelkonen and
Turpeinen (2007)
To cotinine: Km [mg/L] 10.52 (mean 64.9 lM) Messina et al. (1997)
To other metabolites: Kmet [L/h/BW] 0.1674 Teeguarden et al. (2013)
Renal clearance [L/h/BW] 0.036 Teeguarden et al. (2013)
Tissue-to-blood partition coefﬁcients
Liver 1.42 Schmitt (2008)
Poorly-perfused tissues 0.39
Highly-perfused tissues 1.62
Skin 0.38
Brain 2.63
Lungs 1.32
Kidney 1.34
GI tract 0.58
Adipose tissue 0.19
Oral model
Dissolution from tablet Diss [1/h] 0.235 Optimized
Absorption rate from stomach kastm [1/h] 0.006 Optimized
kaSI [1/h] 0.1 (tablet) Optimized
1 (straw)
Stomach emptying rates: kmax [1/h] 8.16 Loizou and Spendiff (2004)
Stomach emptying rates: kmin [1/h] 0.005 Loizou and Spendiff (2004)
Absorption rate from large intestine kaLI [1/h] 0.1 Optimized
Elimination rate from large intestine kelLI [1/h] 0.1 Optimized
Dermal model
Diffusion coefﬁcient in stratum corneum DSC [cm2/h] 1.6  1005 Optimized
Diffusion coefﬁcient in viable epidermis DVE [cm2/h] 9.6  1005 QSAR predicted (see text)
Release of nicotine from patch k [1/h] 0.06 optimized
Partition coefﬁcient between patch and stratum corneum
PCSC
0.4 Optimized
Partition coefﬁcient between stratum corneum and viable
epidermis PCSCVE
1.518 QSAR predicted (see text)
Blood-to-plasma concentration ratio RBP 1.2 ADMET predictora
Inhalation model
Blood/air partition coefﬁcient logPCblood,air 4.743 QSAR predicted (Buist et al., 2012)
Water/air partition coefﬁcient PCwater,air 6000 Optimized
a http://www.simulations-plus.com/Products.aspx?pID=13.
VENOUS BLOOD CONCENTRATION
HEART RATE
TOLERANCE
Fig. 4. Effect compartment – toxicodynamics.
1 Available from The Comprehensive R Archive Network website: http://cran.r-
project.org/ (last access: 16.12.2013).
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E ¼ E0 þ S  ðfu  CvenÞ
y
1þ CAntCAnt;50
 y ð3Þ
Where:
E is the effect on heart rate,
E0 is base-line effect,
Emax is the maximal effect,
CAnt is the antagonist concentration [mg/L] (with respect to
venous blood volume Vven),
Cven is the venous blood concentration of a chemical causing
effect – a stimulant [mg/L],Cven,50 is the venous blood concentration of a chemical causing
50% of the maximal effect [mg/L],
ka,Ant and kel,Ant – are formation and elimination rates [L/h] of
the antagonist,
fu – free fraction of a stimulant,
S – is equal to the ratio of Emax (maximal effect)/(Cven,50)y (con-
centration of a chemical causing half of the effect),
CAnt,50 – the concentration of non-competitive antagonist (toler-
ance) attainable for a steady-state stimulant concentration,
y – exponent introduced as a deviation from the standard
hyperbolic model.
The Sigmoid model parameters are listed in Table 3. Nicotine
patch data were used to calibrate the exponent (y) for exercise
conditions.
All the mathematical equations were programmed in R by
combining functionalities of the following R packages: deSolve,
ReacTran, PK and FME.1 Ordinary differential equations (ODEs) were
solved by the method lsoda available in the deSolve package, which
switches automatically between stiff and non-stiff methods. The
method of lines was used to solve PDEs.
Table 3
Toxicodynamic parameters for nicotine.
Parameter Value References
E0 [bpm] At rest: 61.2 Porchet et al. (1988)
At rest: 64 Fattinger et al. (1997)
During exercise: 145 Mündel and Jones (2006)
S [bpm/mg/L] 1000 Porchet et al. (1988)
ka,Ant [mg/L] 3 Optimized
kel,Ant [mg/L] 6 Optimized
C50,Ant [mg/L] 0.00772 Porchet et al. (1988)
y 1 (at rest)
0.6 (during exercise) Optimized
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Selected daily dosing conditions for nicotine together with web
and literature references are presented in Table 4. They were
selected for resting conditions and used unchanged for ongoing
exercise to show the difference in heart rate changes at identical
internal concentration levels. Only cigarette smoking was slightly
modiﬁed by increasing the respiratory rate for the exercise condi-
tion. Daily dosing included the following consumption statistics:
(a) Smoked cigarettes per day of usual brand (1.2 mg over
4 min) (Benowitz et al., 1982):
- Occasional smokers – between 1 and 5 cigarettes per day
(average 3 per day, one very 4 h)
- Light smokers – between 6 and 10 cigarettes per day (aver-
age 8 per day, one every 2 h)
- Regular smokers – between 11 and 20 cigarettes per day
(assume 14 per day, one every 1 h)
- Heavy smokers – 21 or more cigarettes per day (assume 21
per day, one every 30 min)
(b) Nicotine patches:
- nicotine transdermal patch 7 mg applied once daily
(Area = 22 cm2)
- nicotine transdermal patch 14 mg applied once daily
(Area = 22 cm2)Table 4
Selected average daily exposure to nicotine.
Exposure route Exposed amount
Cigarettes 1.2 mg (usual brand) per 4 min
Dermal patch 7,14,21,42 mg per 24 h
Oral capsule nicotine lozenges 2, 4 mg
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Fig. 5. Single (left) and repeated (right) oral absorption of nicotine using th- nicotine transdermal patch 21 mg applied once daily
(Area = 22 cm2)
- nicotine transdermal patch 42 mg (2 patches: 21 mg +
21 mg) applied once daily (Area = 2.22 cm2 = 44 cm2)
(c) nicotine lozenges – we assume dissolution rate from matrix
calibrated according to (Green et al., 1999)
- 2-mg and 4 mg-nicotine applied lozenges every 1–2 h for
10 h. In this way, no more than 20 lozenges are used per
day.
3. Results
3.1. Toxicokinetics of nicotine
3.1.1. Oral absorption
Simulated oral nicotine administration plasma data (via the
Straw) used for the model calibration are shown in Fig. 5-left for
single dose applications and Fig. 5-right for repeated dosing in
accordance with experimental design speciﬁed in the reference
source (D’Orlando and Fox, 2004). In this experiment it was noted
that 8-times repeated administration of the highest dose of 12 mg
did not show signiﬁcant differences in plasma concentrations
when compared to lower dosing of 8 mg. The authors explain that
it is not clear whether it is due to limitations in the absorption of
nicotine or simply variability in the patient population. The model
simulations with assumed unchanged and constant parameters
produced much higher results for the highest dose than the exper-
imental values.
Oral absorption of nicotine in capsules (Green et al., 1999) with
modelled dissolution from a coated matrix used for PBTK model
validation is shown in Fig. 6. Only non-smokers participated in this
experiment therefore the PBTK model simulations (with optimized
parameters for smokers) clearly showed lower clearance than
expected. Metabolism for nonsmokers would require ca. 1.2 times
faster liver metabolism of nicotine provided there is no other elim-
ination route. Renal clearance of nicotine was not among the most
sensitive model parameters and increasing its value would not giveNumber per day References
3,8,14,21 Benowitz et al. (1982), Fagerström (2005),
National Tobacco Control Ofﬁce (2002)
1 emc (2014), Hamilton Health Sciences (2014)
5, 10 MedlinePlus (2014)
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Fig. 6. Oral absorption of nicotine in capsules (single dose) in nonsmokers.
Experimental data (1) taken from Green et al. (1999).
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serum of non-smokers.
3.1.2. Inhalation of nicotine
Fig. 7 shows blood concentrations of smokers after repeated
smoking every 30 min for 4 min (doses = 0.4, 1.2 mg of nicotine)
and for 3 min (dose = 2.5 mg of nicotine). We assumed that there
was a constant inhaled nicotine concentration of absolute dose/
0.05 [mg/L] and average smoking time of 4 min for low and regular
doses, and 3 min for a high dose, to obtain better representation of
experimental data. Moreover, we did not take into account metab-
olism of nicotine in the respiratory tract.0
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Fig. 7. Inhalation of nicotine via repeated smoking in smokers
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Bannon et al. (1989) and (2) from (Gupta et al., 1993).3.1.3. Dermal absorption of nicotine
Finally, dermal absorption of nicotine from patches is given in
Fig. 8 (left) for single 24-h exposure and in Fig. 8 (right) for pro-
longed exposure (one nicotine patch per day up to 200 h) used in
the calibration step (Bannon et al., 1989). In case of prolonged
exposure, the model simulations were only slightly higher than
the sampled experimental results. These experimental points were
measured plasma concentrations prior to the application of a new
nicotine patch (at the end of 24 h) – they are not peak concentra-
tions resulting after a given application. That is why the model
simulations, at ﬁrst glance, appear ca. 4 times higher. There were
small differences reported between measured plasma AUC of
nicotine on day 1 and day 7 (Bannon et al., 1989) indicating no
signiﬁcant nicotine accumulation following chronic transdermal
delivery. The model validation performed for a single application
of 36 mg of nicotine in a patch (Gupta et al., 1993) is also shown
in the Fig. 8 (left).
3.2. Toxicodynamics of nicotine
Sigmoid model predictions of increased heart rate are presented
in Fig. 9 (left) for nicotine i.v. injections twice every 1, 2 and 3.5 h (at
rest). Fig. 9 (right) shows the effect of nicotine patch on heart rate
throughout the cycling exercise. The toxicodynamic parameters
calibrated for intravenous nicotine injection at rest, that include
tolerance formation and elimination, the ratio of Emax (maximal
effect)/(Cven,50)y and CAnt,50 (but with a different base-line effect
recorded in this experiment (Damirchi et al., 2009)) gave good20
Exp.Data (1) low nicotine
Exp.Data (1) usual brand
Exp.Data (1) high nicotine
Simul. Low nicotine (0.4mg)
Simul. usual brand (1.2mg)
Simul. high nicotine (2.5mg)
. Experimental data (1) taken from Benowitz et al. (1982).
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Fig. 9. Heart rate after double infusion of nicotine (left, at rest) and single dermal administration of nicotine patch (right, at exercise). Experimental data (1) taken from
Porchet et al. (1988) and (2) from Mündel and Jones (2006).
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Fig. 10. Simulated blood concentrations of nicotine for selected daily repeated exposure to cigarettes (1.2 mg over 4 min) –at rest (left), during exercise (right).
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exercise but an exponent smaller than 1 was necessary to obtain
good ﬁtting of experimental data. However, the need for this expo-
nent may arise from the inﬂuence of exercise intensity on heart
rate, smoker–nonsmoker differences in acute responses to nicotine
(since nonsmokers data were used to calibrate the PBTDmodel dur-
ing exercise; Mündel and Jones, 2006) or the combined effect of
these factors. Additional experiments would be necessary to
explore these factors.
3.3. Application of PBTK/TD models to simulate concentration–time
proﬁles in blood and the effects of nicotine on heart rate following
daily exposure proﬁles
In all the daily simulations of nicotine, we used a base-line heart
rate of 61.2 [bpm] (Porchet et al., 1988) at rest and 145 [bpm] dur-
ing exercise (Mündel and Jones, 2006).Concentration–time proﬁles simulated for the daily exposure
scenarios for cigarette smoking, nicotine patches and nicotine loz-
enges are shown in Figs. 10–12, whereas the simulated effects on
heart rate are given in Figs. 13–15. Table 5 shows calculated AUC
and peak concentrations for each exposure proﬁle in the blood
and liver. Cigarette smoking was simulated for different respira-
tory rates at rest and during exercise (see Table 1). This is why
there are different blood concentrations in this case when com-
pared to other exposure routes – increasing respiratory rate from
840 [1/h] to 1080 [1/h] produces ca. 1.5 times higher AUC and only
slightly higher Cmax values when compared to resting conditions.
Table 6 provides estimates of mean heart rates over the duration
of experiment (up to 48 h) for all four exposure routes.
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Fig. 13. Simulated mean heart rate following cigarette smoking at rest (left) and during exercise (right).
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Fig. 14. Simulated mean heart rate following application of nicotine patches at rest (left) and during exercise (right).
61.2
62.2
63.2
64.2
65.2
66.2
67.2
68.2
0 10 20 30 40
H
ea
rt
 R
at
e 
[b
pm
] 
Time[h] 
2mg 10 times
2mg 5 times
4mg 10 times
4mg 5 times
140
145
150
155
160
165
170
175
180
185
0 10 20 30 40
H
ea
rt
 R
at
e 
[b
pm
] 
Time[h] 
2mg 10 times
2mg 5 times
4mg 10 times
4mg 5 times
Fig. 15. Simulated mean heart rate following application of nicotine lozenges at rest (left) and during exercise (right).
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Simulating the toxicokinetic and dynamic behaviour of nicotine
is complex even when the investigations are limited to the Cauca-
sian population. The ﬁrst modelling difﬁculty arises in accounting
for differences in nicotine kinetics with respect to gender (i.e.,
varying nicotine and cotinine clearance), smoker-nonsmoker sta-
tus (i.e., clearance of nicotine, nicotine binding to tissues, expres-
sion of metabolizing enzymes) and type of smoking – cigar
smokers, users of snuff and chewing tobacco (i.e., rate of rise of nic-
otine) (Hukkanen et al., 2005). This, apart from pharmacodynamic
issues, results in differences in blood/plasma concentrations (espe-
cially in the elimination phase) after single and prolonged expo-
sure to nicotine.
When comparing predicted concentrations with experimental
ones it is clear that the PBTK model performs best for exposurevia the inhalation (cigarette smoking) and oral (with the straw)
routes. Oral nicotine administration in carbomer capsules was also
quite well represented by assuming a ﬁrst-order rate of nicotine
release from the tablet coating in the stomach. However, the model
parameters calibrated previously for smokers did not produce a
good match for the concentration–time proﬁles of nonsmokers.
Absorption was simulated faster and elimination slower than
observed (Green et al., 1999) – ca 1.2 times faster metabolism
would produce better results. Experimental peak concentrations
were achieved 7 h after nicotine dosing in the designed carbomer
(Green et al., 1999) and 1–2 h after dosing with the straw
(D’Orlando and Fox, 2004). Simulated peak levels were at 6.8 and
0.8 h, respectively indicating slightly faster calculated absorption
than the observed one. Dermal exposure was the most difﬁcult
to model especially in the absorption phase. Experiments showed
a peak concentration at 8 h (Bannon et al., 1989), whereas
Table 5
AUC and Cmax values for all the exposures to nicotine.
Exposure route AUC liver AUC blood Cmax liver Cmax blood
Cigarettes
(1.2 mg)
3 per day 0.048 (rest) 0.035 (rest) 0.0061 (rest) 0.0043 (rest)
0.072 (exercise) 0.053 (exercise) 0.0068 (exercise) 0.0048 (exercise)
8 per day 0.121 (rest) 0.0875 (rest) 0.012 (rest) 0.0084 (rest)
0.0482 (exercise) 0.035 (exercise) 0.0073 (exercise) 0.0051 (exercise)
14 per day 0.217 (rest) 0.158 (rest) 0.0219 (rest) 0.0157 (rest)
0.265 (exercise) 0.193 (exercise) 0.023 (exercise) 0.016 (exercise)
21 per day 0.507 (rest) 0.368 (rest) 0.0452 (rest) 0.0324 (rest)
0.724 (exercise) 0.526 (exercise) 0.0478 (exercise) 0.0325 (exercise)
Dermal patches
7 mg 0.159 0.046 0.009 0.003
14 mg 0.318 0.091 0.018 0.005
21 mg 0.477 0.137 0.028 0.008
42 mg 0.956 0.274 0.056 0.016
Nicotine lozenges
2 mg (every 2 h) 0.102 0.043 0.0062 0.0026
2 mg (every 1 h) 0.204 0.086 0.0124 0.0051
4 mg (every 2 h) 0.204 0.086 0.0125 0.0052
4 mg (every 1 h) 0.409 0.172 0.0249 0.0103
Table 6
Predicted mean heart rates over simulation time for 4 administration routes.
Dose Admin. route Base-line heart rate (E0) [bpm] Mean heart rate at rest [bpm] Mean heart rate during exercise [bpm]
2.5 lg/kg BW/min for 30 min 1 h apart i.v At rest = 61.2 69.206 –
2.5 lg/kg BW/min for 30 min 2 h apart i.v At rest = 61.2 69.558 –
2.5 lg/kg BW/min for 30 min 3.5 h apart i.v At rest = 61.2 69.196 –
0.7 lg/kg BW/min for 180 min i.v At rest = 64 71.350 –
Dermal patches
7 mg At rest = 61.2 62.008 154.508
14 mg Dermal during exercise 62.666 158.079
21 mg =145 63.215 160.531
42 mg 64.436 165.256
Cigarettes (1.2 mg)
3 per day At rest = 61.2
8 per day Inhalation during exercise 61.798 154.008
14 per day =145 62.505 151.417
21 per day 63.215 161.235
65.493 164.713
Nicotine lozenges
2 mg (every 2 h) Oral at rest = 61.2 61.968 155.157
2 mg (every 1 h) during exercise 62.606 159.138
4 mg (every 2 h) =145 63.156 159.153
4 mg (every 1 h) 63.621 164.147
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that either the diffusion coefﬁcient in skin or the rate of nicotine
release are not constant over time or that there is a time delay in
nicotine release from the patch. In fact, the measured in vivo
release proﬁles of nicotine are not constant. They were found to
be relatively linear for the ﬁrst 8 h but then the absorption rate
declined (Bannon et al., 1989). Experimental data for repeated
smoking of low, average and high- nicotine brands of cigarettes
resulted in nicotine concentrations in blood rising over the ﬁrst
4–6 h after which they tended to plateau until smoking stopped
(Benowitz et al., 1982). The PBTK model estimated an increase in
blood levels up to the last cigarette (at 15 h) but this growth was
ca. 5.3 times higher within the ﬁrst 7 h. The major limitations of
PBTK modelling in this study were in the underlying assumptions
that: (i) there are no inter-individual and smoker–nonsmoker dif-
ferences in the ADME model parameters; (ii) there is no nicotine
in blood prior to exposure; and (iii) exposure is via only a single
route; (iv) the model includes constant absorption parameters
from the GI tract, respiratory tract and release from a patch and
constant diffusion coefﬁcient of nicotine through skin; (v) thereis a need for using QSARs to predict partitioning between stratum
corneum and viable epidermis as well as diffusion in epidermis
due to lack of experimental data.
Application of the calibrated PBTK model to selected daily expo-
sure scenarios showed that (Table 5):
- As expected, AUC and Cmax in the blood were the highest after
smoking 21 cigarettes per day (every 30 min) when compared
to other exposure routes (AUC in blood was ca. 34% higher than
that of 42 mg patch at rest and 92% higher with faster respira-
tory rate; Cmax in blood was 103% (both at rest and during exer-
cise) higher than after extreme dermal exposure).
- AUC and Cmax in the liver were the highest for dermal applica-
tion of two nicotine patches (42 mg) for 24 h over 44 cm2 skin
area (AUC in liver compared to that of smoking 21 cigarettes
was found 89% (rest) and 32% (exercise) higher, whereas Cmax
in liver was 24% (rest) and 18% (exercise) higher).
- 2 mg of nicotine given orally every hour (10 times a day) is
equivalent to 4 mg given orally every 2 h (5 times a day) in
terms of AUC and Cmax-based results.
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Fig. 16. Comparable exposure scenarios in terms of toxicokinetics – blood results.
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of AUC and Cmax, is more relevant for systemic toxic effects,
comparable exposure results were estimated for: 3 cigarettes
per day  1 dermal patch 7 mg  2 mg of lozenges every 2 h
(5 altogether); 8 cigarettes per day  14 mg dermal patch 
4 mg of lozenges (5 altogether) or 2 mg lozenges (10 altogether)
– Fig. 16.
Our choice of 4-min smoking time in these daily scenarios was
based on the model calibrations with respect to in vivo data
(Benowitz et al., 1982) and other literature studies such as the
one of Mendelson et al. (2008)) in which the tested subjects
smoked each cigarette for 4 min and took one 5 s- puff every
30 s. We assumed the same smoking duration for the exercise con-
ditions and changed only the respiratory rate. By using a smoking
time of 4 min we accounted for the worst-case scenario which is
thus a conservative one in a safety assessment. In reality, there
might be an increase in the puff frequency that makes a cigarette
burn out faster; therefore a shorter time that 4 min could be more
appropriate. To simulate a shorter smoking time would require,
however, the availability of suitable data to verify the model per-
formance in accurately estimating blood concentrations following
smoking during exercise.
As shown in the results and indicated in the literature (Porchet
et al. (1988)), the heart rate is well-described by a two-compart-
ment PBTD model, but a modiﬁcation (introduction of an exponent
in relating the nicotine and antagonist concentrations to observa-
ble effect) might be necessary to obtain a better representation
of heart rate increase during exercise conditions using the TD
parameters calibrated for IV injection at rest (except for a base-line
value). The need for this modiﬁcation may arise from a variety of
factors such as inﬂuence of exercise intensity, population effects,
differences between smokers and non-smokers in terms of nicotine
effects on heart rate, quality of experimental data, exposure route
or combination of them.
TD model simulations indicate that the highest heart rate is
achieved after heavy smoking of 21 cigarettes a day and equals
71.5 [bpm] (at rest, increase by 10.3 [bpm] from base effect) and
196 (during exercise, increase by 51[bpm] from the base effect).
Our simulated heart rate values were in the range of experimental
results published by Papathanasiou et al. for smokers during exer-
cise: 191–193 bpm (Papathanasiou et al., 2013). At resting condi-
tions our simulations indicated lower heart rates due to lower
assumed base-line values than the ones of Papathanasiou et al.
(61.2 vs. 72.8–76.4 bpm). When comparing mean heart rate esti-
mates (Table 6) over up to 48 h we see, that it is dermal absorption
that causes long-lasting higher heart rate. The reason behind it is
probably pro-longed nicotine release from a patch and therefore
a longer nicotine presence in the blood.Whereas the application of PBTK–TD models in the simulation
of selected daily exposure scenarios of nicotine has been usefully
illustrated, further experiments are necessary to validate the
modelling results and conclusions, especially given that environ-
mental, genetic and other subject-speciﬁc differences are likely
to affect human responses to nicotine. The approach illustrated
here and the results obtained could nevertheless be used to
guide the design of experiments that would help to assess the
safety of nicotine-containing products. The applicability of PBTK
modelling should be further investigated with respect to
different exposure scenarios including consideration of other
nicotine-containing products, the effects of other substances on
nicotine ADME proﬁles, and combined (multi-route) exposure
scenarios.5. Conclusions
A joint PBTK–TD model for the Caucasian population, calibrated
and validated by using various published nicotine blood/plasma
concentrations (single and repeated dosing), has been applied to
estimate and compare several daily exposure scenarios: cigarette
smoking, oral and dermal absorption and their effects on acute
increase in heart rate at rest and during exercise. Frequent
cigarette smoking shows high AUC and Cmax in the blood, and
nicotine-rich dermal patches produce high AUC and Cmax in the
liver. The resulting toxicokinetics in blood after smoking of 3
cigarettes per day was found comparable to the use of a single
7 mg-dermal patch and 5 2 mg-lozenges every 2 h whereas
smoking of 8 cigarettes per day was found comparable to a single
use of 14-mg dermal patch or 10 2-mg lozenges every hour. How-
ever, the effects of smoking on heart rate are deﬁnitely higher than
any of the investigated methods for nicotine therapy. Maximal
heart rate while smoking was estimated to be ca. 1.35 times higher
than the base-line value during a cycling exercise and ca.
1.17 times higher at rest. Multi-route exposure to nicotine was
not investigated in this study and would require further experi-
mentation and modelling.Conﬂicts of interest
None.
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Adipose tissue (adp), highly perfused tissues – brain (brn), heart
(hrt), poorly perfused tissues (ppt), remaining organs/tissues (ro),
etc.:
dAorg
dt
¼ forg  Cart  CorgPCorg
 
; Aorgðt ¼ 0Þ ¼ 0;
Cart ¼ CartVart ; Corg ¼
Aorg
Vorg
ðA1:1Þ
where: org = organ name (adp, hpt (brn, hrt), ppt, ro, etc.)
Kidney:
dAkid
dt
¼ fkid  Cart  CkidPCkid
 
 CLR  Ckid
PCkid
; Akidðt ¼ 0Þ ¼ 0;
Ckid ¼ AkidVkid ðA1:2Þ
Liver:
dAliv
dt
¼ FlGIT þ FORMliv þ fliv  Cart  ClivPCliv
 
MET liv;
Alivðt ¼ 0Þ ¼ 0; Cliv ¼ AlivV liv ðA1:3Þ
For a parent compound:
GI tract: FlGIT ¼ fra  fgit  CstmPCgit þ frb  fgit 
CSI
PCgit
þ frc  fgit  CLIPCgit
FORMliv ¼ 0 ðrate of formation of a given metaboliteÞ;
MET liv  metabolism equations
Venous blood:
dAven
dt
¼ fliv  ClivPCliv þ fhpt 
Chpt
PChpt
þ fppt  CpptPCppt þ fro 
Cro
PCro
þ fadp  CadpPCadp
þ fkid  CkidPCkid þ Flskn  f crd  Cven; Avenðt ¼ 0Þ ¼ 0;
Cven ¼ AvenVven ðA1:4Þ
For dermal absorption: Flskn ¼ fskn  CsknPCskn
Oral absorption:
Stomach content:
dAstm;cont
dt
¼ Drt  kastm  Cstm;cont  kGIT  Astm;cont ðA1:5Þ
with: Cstm;cont ¼ Astm;contV stm ; kGIT ¼
kmax
ð1þ kmin  CstmÞ
and:
 admin. via gavage: Drt ¼ 0; Astm;contðt ¼ 0Þ ¼ Dose
 admin. by a coated tablet: Drt ¼ dAstm;cont;dissdt ¼ Diss  Astm;cont;diss;
Astm;cont;dissðt ¼ 0Þ ¼ Dose
Stomach-absorbed quantity:
dAstm
dt
¼ kastm  Cstm;cont þ fra  fgit  Cart  CstmPCgit
 
;
Astmðt ¼ 0Þ ¼ 0; Cart ¼ AartVart ; Cstm ¼
Astm
V stm
ðA1:6Þ
Small Intestine lumen and absorbed quantity:dASI;lumen
dt
¼ kGIT  Astm;cont  ðkaSI þ flowLIÞ  CSI;lumen;
ASI;lumenðt ¼ 0Þ ¼ 0; CSI;lumen ¼ ASI;lumen3
4  V int
  ðA1:7Þ
dASI
dt
¼ kaSI  CSI;lumen þ frb  fgit  Cart  CSI;PCgit
 
;
ASIðt ¼ 0Þ ¼ 0; CSI ¼ ASI3
4  V int
  ðA1:8Þ
Large Intestine lumen and absorbed quantity:
dALI;lumen
dt
¼ flowLI  CSI;lumen  kelLI þ kaLIð Þ  CLI;lumen;
ALI;lumenðt ¼ 0Þ ¼ 0; CLI;lumen ¼ ALI;lumen1
4  V int
  ðA1:9Þ
dALI
dt
¼ kaLI  CLI;lumen þ frc  fgit  Cart  CLIPCgit
 
;
ALIðt ¼ 0Þ ¼ 0; CLI ¼ ALI1
4  V int
  ðA1:10Þ
Skin absorption:
Skin surface:
ðt < tapplÞ AbsRate ¼ k  Cform; ðt  tapplÞ AbsRate ¼ 0 ðA1:11Þ
Where: tappl is the application time of a patch on the skin.
Stratum Corneum (SC):
dCSC;i
dt
  qSC;iþ1  2  qSC;i þ qSC;i1ðLscN Þ
; i ¼ 1 : NCSC;i ¼ ASC;iVSCi
ðA1:12Þ
where: qSC:;i ¼ DSCi 
CSC;iþ12CSC;iþCSC;i1
ðLscN Þ
; i ¼ 1 : N
Initial and boundary conditions:
CSCðt ¼ 0Þj06x6LSC ¼ 0
dCSC
dt ðt > 0Þjx¼0 ¼ k  Cform
DSC  dCSCdx ðt > tapplÞjx¼0 ¼ 0
CSCðt > 0Þjx¼0 ¼ PCSC  Cform
CSCðt > 0Þjx¼LSC ¼ PCSCVE  CVE
Viable Epidermis (VE):
dCVE; j
dt
 qVE; jþ1  2  qVE; j þ qVE; j1ðLveM Þ
; j ¼ 1 : M CVE; j
¼ AVE; j
VVE; j
ðA1:13Þ
where: qVE; j ¼ DVE; j  CVE; jþ12CVE; jþCVE; j1LVE
M
  ; j ¼ 1 : M
Initial and boundary conditions:
CVEðt ¼ 0Þj06y6LVE ¼ 0
CVEðt > 0Þjy¼0 ¼ CSC;i¼NPCSCVE
DSC
dCSC
dx jx¼LSC ¼ DVE 
dCVE
dy jy¼0
CVEðt > 0Þjy¼LVE ¼ PCskn  Cskn
Dermis and mix with the blood:
dAskn
dt
¼ fskn  Cart  CsknPCskn
 
þ qVE; j¼M  Area; Asknðt ¼ 0Þ ¼ 0;
Cskn ¼ Askn
103  Vde ðA1:14Þ
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Inhaled air tract:
dAINH
dt
¼ ALV  Cexp
PCwater;air
þ2 RR CEXH ALV  CINHPCwater;air  2 RR  CINH;
AINHðt ¼ 0Þ ¼ 0; CINH ¼ AINHVAT ðA1:15Þ
Exhaled air:
dAEXH
dt
¼ALV  Clng
PCwater;air
þ2 RR CINHALV  CEXHPCwater;air2 RR CIEXH;
AEXHðt¼0Þ¼0; CEXH¼AEXHVAT ðA1:16Þ
Lungs:
dAln g
dt
¼ fln g  Cven  PCblood;air  Cln gPCln g
 
þ ALV  CINH
PCwater;air
 ALV
PCwater;air
 CIlng
PClng
; Aln gðt ¼ 0Þ ¼ 0; Cln g ¼ Aln gV ln g ðA1:17Þ
Arterial blood:
dAart
dt
¼ f crd  Cln g
PCln g
 PCblood;air  Cart
 
; Aartðt ¼ 0Þ ¼ 0 ðA1:18ÞReferences
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